Evidence for the involvement of B lymphoid cells in polycythemia vera and essential thrombocythemia.

Previous studies with the X-chromosome-linked glucose-6-phosphate dehydrogenase (G6PD) as a marker of cellular mosaicism demonstrated that polycythemia vera (PV) and essential thrombocythemia (ET) are clonal disorders of hematopoietic stem cells that can differentiate to erythrocytes, granulocytes, and platelets. To determine if the involved stem cells could also differentiate along the B-lymphoid pathway, we studied one woman with PV and one woman with ET. Of 117 Epstein-Barr virus-transformed B-lymphoblastoid lines expressing a single G6PD derived from the patient with PV, 108 expressed G6PD type A, the type characteristic of the abnormal clone. The ratio of 108:9 was significantly different from the one to one ratio predicted for this patient, which suggested that at least some circulating progenitors for B-lymphoid cell lines differentiate from the stem cell involved by the disease. Results obtained from the patient with ET were similar--104 of the 109 lymphoblastoid lines monotypic for G6PD expression displayed the enzyme type found in the abnormal clone of marrow cells. Therefore, in these patients, PV and ET, like chronic myelogenous leukemia, involve a stem cell pluripotent for the lymphoid as well as the myeloid series.

[1]  P. Fialkow,et al.  Evidence for a multistep pathogenesis of a myelodysplastic syndrome. , 1984, Blood.

[2]  B. Hecht,et al.  Characterization of Epstein-Barr virus-carrying cell lines established from chronic lymphocytic leukemia. , 1983, Cancer research.

[3]  M. Epstein,et al.  Interaction of Epstein-Barr virus with leukaemic B cells in vitro. I. Abortive infection and rare cell line establishment from chronic lymphocytic leukaemic cells. , 1982, Clinical and experimental immunology.

[4]  V. Najfeld,et al.  Evidence for a multistep pathogenesis of chronic myelogenous leukemia. , 1981, Blood.

[5]  G. Klein,et al.  Establishment of a lymphoid cell line from leukemic cells of a patient with chronic lymphocytic leukemia , 1980, International journal of cancer.

[6]  G. Klein,et al.  Chromosome analyses of lymphoid cell lines derived from patients with chronic lymphocytic leukemia , 1980, International journal of cancer.

[7]  V. Najfeld,et al.  Involvement of the B-lymphoid system in chronic myelogenous leukaemia , 1980, Nature.

[8]  J. Adamson,et al.  Polycythemia vera: stem-cell and probable clonal origin of the disease. , 1976, The New England journal of medicine.

[9]  P. Fialkow.  Primordial cell pool size and lineage relationships of five human cell types* , 1973, Annals of human genetics.

[10]  Z. Bentwich,et al.  SHEEP RED CELL BINDING TO HUMAN LYMPHOCYTES TREATED WITH NEURAMINIDASE; ENHANCEMENT OF T CELL BINDING AND IDENTIFICATION OF A SUBPOPULATION OF B CELLS , 1973, The Journal of experimental medicine.

[11]  S. Gartler,et al.  Clonal origin of chronic myelocytic leukemia in man. , 1967, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P. Fialkow.  Cell lineages in hematopoietic neoplasia studied with glucose‐6‐phosphate dehydrogenase cell markers , 1982, Journal of cellular physiology. Supplement.

[13]  G. Faguet,et al.  Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. , 1981, Blood.

[14]  R. Berger,et al.  Philadelphia chromosome positive blood B lymphocytes in chronic myelocytic leukemia. , 1981, Leukemia research.

[15]  P. Fialkow.  Clonal and Stem Cell Origin of Blood Cell Neoplasms , 1980 .

[16]  A. Denman,et al.  ORIGIN OF SOME LYMPHOCYTES FROM LEUKEMIC STEM CELLS , 1978 .

[17]  R. Sparkes,et al.  Cellulose acetate electrophoresis of human glucose-6-phosphate dehydrogenase. , 1969, The Journal of laboratory and clinical medicine.